Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UNIVERSITETET I OSLO currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners, meaning that every active matter is being reviewed by a different individual. This distribution suggests that the company's prosecution experience is decentralized, with no examiner overlap currently present in the pending portfolio.
The portfolio spans 3 distinct art units, indicating some technical variety within the biotechnology and pharmaceutical fields. The busiest examiner, ROBINSON, KYLE G, is responsible for 1 pending office action. This confirms that even the most active examiner handles only a single case, as the 4 pending office actions are spread across 4 distinct examiners.
Practitioners must navigate the specific requirements of 3 distinct art units, which likely have different examination standards. Because 4 distinct examiners are involved in the 4 pending office actions, there is no opportunity to apply insights from a single examiner to multiple cases. The various art units represent the technical landscape UNIVERSITETET I OSLO is currently navigating in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, KYLE G | 1 | 11.7% | +16.6% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 70.8% | +31.8% |
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19131342 | ASSESSING HEALTH OF A HEART VALVE | ROBINSON, KYLE G | — |
| 18033911 | PHOSPHATE BASED TARGETS | DICKINSON, PAUL W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19131342 | ASSESSING HEALTH OF A HEART VALVE | ROBINSON, KYLE G | — |
| 18692219 | BINDING PROTEINS FOR TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TDT) | EDGINGTONGIORDANO, FRANCESCA | — |
| 18247498 | TREATMENT FOR VIRAL INFECTION | KUCKLA, ANNA GRACE | — |
| Art Unit | Apps |
|---|---|
| 3685 | 1 |
| 1618 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19131342 | ASSESSING HEALTH OF A HEART VALVE | ROBINSON, KYLE G | 3685 | §101§102§103§112 | Non-Final OA | — | Pending | May 20, 2025 |
| 18692219 | BINDING PROTEINS FOR TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TDT) | EDGINGTONGIORDANO, FRANCESCA | — | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18033911 | PHOSPHATE BASED TARGETS | DICKINSON, PAUL W | 1618 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18247498 | TREATMENT FOR VIRAL INFECTION | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | — | Pending | Mar 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial